结节阴性阴茎状细胞癌中复发,转移和死亡的预测因素:一项回顾性多中心队列研究
Katie A O'Connell1,2, Jacob L Thomas3,4, Fadi Murad1
1Brigham & Women's/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
概括
历史的平衡炎和,以及差差分化,身体入侵和围神经入侵 (PNI),是阴茎状细胞癌 (PSCC) 结果的关键预后因素.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 病理学 病理学 病理学
背景情况:
- 阴茎状细胞癌 (PSCC) 与显著的发病率和死亡率有关.
- 关于预后因素的数据有限,特别是在PSCC中转移的发展.
研究的目的:
- 确定临床结节阴性PSCC患者不良结果的独立预后因素.
- 评估结果包括局部复发 (LR),转移和疾病特异性死亡 (DSD).
主要方法:
- 一个32年的回顾性多中心队列研究.
- 包括265名经组织学诊断的PSCC患者.
- 开发基于患者和瘤特征的预测模型.
主要成果:
- 确定了五个独立的预后因素导致不良结果:平衡炎史,差异化不良,身体入侵,周围神经入侵 (PNI) 和先前的发病史.
- 差异化,PNI和身体入侵显著与转移风险增加有关.
- 对于具有PNI,身体入侵和差差分化的瘤,观察到5年累积转移发生率更高.
结论:
- balanitis,phimosis,PNI,身体入侵和差异化的历史是PSCC中不良结果的独立风险因素.
- 由于差差分化和PNI目前被归类为T1b疾病,PSCC的预后阶段可能会得到改善.
相关概念视频
Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


